Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 3Recruiting 2Completed 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pathologic Complete Response 1Breast Neoplasms 1

Interventions

Paclitaxel 2Irinotecan 2Carboplatin 2pertuzumab 1ledipasvir 1genexol-PM 1elbasvir-grazoprevir drug combination 1dolutegravir 1apatinib 1Vinorelbine 1Trastuzumab 1Tissue Banks 1Tai Ji 1Surgical Procedures, Operative 1Sofosbuvir 1S 1 (combination) 1Ritonavir 1Ribavirin 1Radiotherapy, Intensity-Modulated 1Qigong 1Physical Examination 1Oxaliplatin 1Nucleosides 1Nivolumab 1Magnesium 1Levoleucovorin 1Interleukin-2 1Immunotherapy 1Immune Checkpoint Inhibitors 1Hydralazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER_GOV × Epirubicin × Clear all
NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡